Efficacy of alectinib in advanced ALK-positive non-small cell lung cancer: Results from the Russian multicenter KARL-005 study
Introduction. Tyrosine kinase inhibitors, specifically alectinib, have significantly improved the prognosis for patients with advanced ALK-positive non-small cell lung cancer (ALK+ aNSCLC). National multicenter real-world data are essential to validate these outcomes within a broader clinical population. Aim....